Part 11 Regulation Revision Not Imminent

Washington Drug Letter
A A
Although the FDA is rebidding its contract for a consultant to help rewrite the Part 11 regulation and related guidance documents, publication of a revision is not expected in the near future.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $10.00